Treatment of immunoglobulin A nephropathy with targeted-release budesonide (Kinpeygo ^®▾ )

This article explores the evolving treatment of IgA nephropathy, highlighting targeted-release budesonide as the first licensed therapy to reduce proteinuria and slow disease progression when combined with optimised supportive care. This article was sponsored by Stada UK. Stada UK had no involvement in the creation of the content, which was independently developed by the authors Richard Hull, Ayat Faggad and Lisa Willcocks in partnership with MA Healthcare. Stada UK reviewed the article for technical accuracy and compliance only. Prescribing information and adverse event reporting can be found at the end of this article. UK-KINPE-215 | February 2026